A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954

Phase 1 Completed 24 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of VIS954 compared with placebo in healthy adult participants.

Timeline

Start: 2025-03-13
Primary completion: 2026-02-03
Completion: 2026-02-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VIS954	Monoclonal antibody	—	Subcutaneous

Indications

No indication recorded.